Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement

Background: Cancer of unknown primary (CUP), which accounts for 3%–5% of new cancer cases every year, involves the presence of a type of histologically confirmed metastatic tumors whose primary site cannot be confirmed by conventional diagnostic methods. This difficulty in identifying the primary si...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Ling, Lin, Jietao, Li, Hanhan, Sun, Lingling, Wang, Shubo, Chen, Yaoxu, Chen, Hanrui, Lin, Lizhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899799/
https://www.ncbi.nlm.nih.gov/pubmed/36755949
http://dx.doi.org/10.3389/fphar.2023.997760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899799/
https://www.ncbi.nlm.nih.gov/pubmed/36755949
http://dx.doi.org/10.3389/fphar.2023.997760

Ejemplares similares